Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Non-Small Cell Lung Cancer Study

Canada NewsWire August 26, 2015

MEDIA ADVISORY - Oncolytics Biotech® Inc. to Participate in the 35th Annual Canaccord Genuity Growth Conference

Canada NewsWire August 12, 2015

Oncolytics Biotech® Inc. Announces 2015 Second Quarter Results

Canada NewsWire August 6, 2015

MicroCap Report: Callinex Mines (V.CNX) gets capital injection for Pine Bay exploration

Stockhouse Editorial July 13, 2015

Oncolytics Biotech® Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic Cancer

Canada NewsWire July 6, 2015

Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International Conference on Oncolytic Virus Therapeutics

Canada NewsWire June 15, 2015

Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders

Canada NewsWire June 12, 2015

Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of Shareholders

PR Newswire June 9, 2015

Oncolytics Biotech® Inc. Provides Update at AGM on Planned Registration Program for REOLYSIN®

PR Newswire June 8, 2015

/C O R R E C T I O N -- Oncolytics Biotech Inc./

Canada NewsWire June 6, 2015

Oncolytics Biotech® Inc. Announces Details of 2015 Annual Meeting of Shareholders

Canada NewsWire June 5, 2015

Media Advisory - Oncolytics Biotech® Inc. to Participate in the LD Micro Invitational Conference

Canada NewsWire June 2, 2015

Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors

Canada NewsWire May 19, 2015

Oncolytics Biotech® Inc. Announces 2015 First Quarter Results

Canada NewsWire May 7, 2015

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer

PR Newswire May 6, 2015

Oncolytics (T.ONC) secures orphan drug status from EMA for pancreatic cancer

Stockhouse Editorial April 29, 2015

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer

PR Newswire April 29, 2015

Oncolytics Biotech® Inc. Announces Extension to Regain Compliance with Nasdaq's Minimum Bid Price Rule

Canada NewsWire April 28, 2015

Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual Meeting

Canada NewsWire April 20, 2015

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas

Canada NewsWire April 17, 2015